Clinical Observation And Efficacy Analysis Of Intravitreal Injection Of Ranibizumab In The Treatment Of Wet Age-related Macular Degeneration

ObjectiveWet age-related macular degeneration(w-AMD)is the main clinical type of age-related macular degeneration(AMD),which causes visual loss.Its pathogenesis is complex.At present,anti-VEGF drugs have been widely used in the clinical treatment of w-AMD,and achieved good results.The aim of this study was To analyze the clinical efficacy and safety of intravitreal injection of ranibizumab in the treatment of wet age-related macular degeneration(w-AMD).MethodsIt is retrospective case study.23 patients(26 eyes)with w-AMD confirmed by clinical examination were treated with intravitreal injection of ranibizumab 0.5 mg every month for the first three months.The patients were followed up for three months.The best corrected visual acuity(BCVA),central retinal thickness(CRT(Inner Thickness,Full Thickness)),neovascularization area(outer retinal,choriocapillaris)and operative complications were compared and analyzed before and1,2 and 3 months after treatment by rank sum test.ResultsThe number of injections of ranibizumab was 3 times.At the last follow-up examination of 26 eyes after treatment,BCVA was significantly higher than that before treatment(P < 0.001).CRT was significantly lower than that before treatment(P < 0.001).The area of CNV was significantly smaller than that before treatment(P <0.001).ConclusionsThese results suggest that intravitreal injection of ranibizumab is safe and effective in the treatment of wet age-related macular degeneration,with an improvement in the visual acuity,retinal thickness and neovascularization.